BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol.
Authors: Patrycja Bielawie, Ewa Harasim-Symbor, Adrian Chabowski
Frontiers in Endocrinology, 4 March 2020
—
Currently, an increasing number of diseases related to insulin resistance and obesity is an alarming problem worldwide. It is well-known that the above states can lead to the development of type 2 diabetes, hypertension, and cardiovascular diseases. An excessive amount of tria…
The Endocannabinoid System of Animals
This review paper by Dr. Robert Silver gives an overview of the ECS in animals and highlights it as a topic of interest for emerging therapeutics.
Drug interactions with cannabinoids.
Authors: Tony Antoniou, Jack Bodkin, Joanne M.-W. Ho
CMAJ : Canadian Medical Association journal, 2 March 2020
—
Cannabinoid levels can be increased by other medications. Cannabinoids can affect levels of other drugs. Smoking marijuana can increase clearance of some drugs. Additive effects can occur with other drugs. There are potential “red flag” interactions.
Cannabis education needs assessment among Canadian physicians-in-training.
Canadian researchers found that the average training from physicians in training was 25% less than what they desired and that further training was paramount for them to engage in cannabis for therapeutic purposes (2020).
The influence cannabidiol on delayed onset of muscle soreness
CBD appears to have a significant influence on muscle soreness associated with exercise induced muscle damage and delayed onset of muscle soreness when consumed immediately after strenuous exercise.
Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions.
Authors: Joshua D. Brown
Journal of Clinical Medicine, 28 February 2020
—
Tetrahydrocannabinol (THC) is the primary psychoactive ingredient in cannabis. While the safety of THC and cannabis has been extrapolated from millennia of recreational use, medical marijuana programs have increased exposure among medically complex individuals with comorbid co…
Value Of Cannabis Based Medicine (podcast)
Dr. Sherry Yafai is an ER doctor who also integrates cannabis-based medicine in her clinical practice at The Releaf Institute. In this interview with Joe Lemon, she explores the reasons why cannabis- informed healthcare providers are needed more and more.
Cannabis For Senior Mental Health
Dr. Phillip Grob, a geriatric psychiatrist, discusses the potential applications of cannabis for dementia and mental health challenges in the senior population.
Opiates & Cannabis: Current Perspectives & Case Studies
Dr. Sherry Yafai of the Releaf Institute discusses the applications of cannabis to reduce or replace the use of opiate drugs. She outlines the opioid epidemic and how cannabis may be used as a tool for harm reduction.
The Antitumor Properties of Cannabis: Preclinical Evidence
Dr. Cristina Sanchez, a biochemist with over 20 years of experience as a cannabinoid researcher, outlines the preclinical evidence of cannabinoids on different types of cancer.
From Cultivar to Chemovar: An Update on Cannabis Varieties
Dr. Arno Hazekamp discusses the intricacies of the Sativa/Indica debate. He describes metabolic characterists of cannabis constituents and the characteristics of hybrids. Originally recorded at the SCC Quarterly Meeting in March of 2018.
Tourette Syndrome: Clinical Presentation, Underlying Pathology and Treatment Options
Dr. Kirsten Muller-Vahl, is a physician specializing in neurology and psychiatry, is the world’s authority on cannabis and Tourette’s syndrome. She presents “Tourette Syndrome: Clinical presentation, underlying pathology and treatment options” at the February SCC Quarterly Meeting on January 4, 2018.